| July 31, 2014 | ISSUE NUMBER 362 VOL 4 |
Top Story
Managing High-Priced, US Biotech Rxs in Canada
As the “Saga of Sovaldi” continues to unfold in the U.S., it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing a similar Sovaldi situation, as well as the other new, high cost, American biotech products that are beginning to appear there. Tom Norton reports ...Read more
ZS AccessMonitorTM finds 49% of MDs “access restricted” for sales reps.
 Read the report
to learn about the present and future of sales rep access to MDs in pharma.
Pricing
PCMA Releases Hep C Medicare Part D Impact Study
As the controversy over Sovaldi’s $84,000 per therapy cost continues to build, the Pharmaceutical Care Management Association has released a study on the impact of the new Hepatitis C drugs on the overall costs to the US Medicare Part D pharmaceutical program
...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence —  by downloading this eBook
.
Regulatory
Sandoz Wins Biosimilar Filing Race
After months of speculation about prospects for biosimilar development in the U.S., Novartis announced last week that FDA has accepted Sandoz’ biologics license application (BLA) for a similar version of Amgen’s Neupogen (filgrastim). Jill Wechsler reports
...Read more
Seeing the Whole Picture: Harnessing the Power of Data to Drive Smarter Marketing Decisions
Thursday, August 7, 2014 at 1:00 PM EDT
To Registere at:
 www.pharmexec.com/picture
M&A
Only Fools Rush In: The Importance of Pre-Acquisition Due Diligence
One reason why compliance should have a seat at the M&A table early on is so that a company’s compliance and legal teams stay informed of upcoming deals in the pipeline in order to marshal the necessary resources prior to the announcement of a takeover bid, writes Severin Wirz
...Read more
Are Your Patient Access Solutions Performing up to Your Expectations?
Wednesday, August 6, 2014 at 1:00 PM EDT
To Registere at:
 www.pharmexec.com/patientaccess
|
|
|
|
 //Craig Fraser was named Chief Operating Officer of Aegerion Pharmaceuticals, Inc. (Cambridge, MA).//Abide Therapeutics (San Diego, CA) appointed Nancy Thornberry to its Board of Directors.//Egalet Corporation (Wayne, PA) announced the appointment of Jeffrey M. Dayno, M.D., as Chief Medical Officer.//Arthur J. Tipton, Ph.D., President and CEO of Southern Research Institute (Frederick, MS) was elected President of the Controlled Release Society (Birmingham, AL) for the 2014–2015 term.//
Packaging Coordinators, Inc. (Philadelphia, PA) announced that it is to acquire Penn Pharma. Penn is headquartered in Tredegar, UK, and operates regional offices in New Hope, PA, and Tokyo, Japan.// |
|
|
|
|
|
 |
|
|
| |
|
 |
|
 |
The FDA Safety & Innovation Act (FDASIA) was signed into law two years ago. Where has the most progress been made in implementation?
|
|
|
|
